Program Description
The choice of treatment for chronic lymphocytic leukemia can be influenced by patient-specific features. The use of small molecule inhibitors of Bruton tyrosine kinase and B-cell lymphoma 2 have shifted the treatment landscape to include oral therapy options. This podcast will feature a discussion of clinical data supporting the use of novel and emerging combination oral therapies for patients with chronic lymphocytic leukemia.
Target audience: Health-system and oncology pharmacists
Type of activity: Knowledge
Release date: June 30, 2022
Expiration date: June 30, 2023
Time to complete activity: 0.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Differentiate novel therapies for the treatment of chronic lymphocytic leukemia by pharmacologic properties and special considerations for use
- Associate drug therapy and safety and efficacy information with treatment selection for patients with chronic lymphocytic leukemia
Katherine Tobon, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
Moffitt Cancer Center
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-319-H01-P. The activity is available for CE credit through June 30, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, listen to the podcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Katherine Tobon, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms